Actively Recruiting
Phase 1 Trial to Develop a Controlled Human Infection Model Using RG-ATexas712017 H3N2 Influenza in Healthy Adults Aged 18 to 45 via Intranasal Challenge
Led by Dalhousie University · Updated on 2026-08-27
32
Participants Needed
1
Research Sites
34 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are establishing an influenza Controlled Human Infection Model CHIM in Canada to study the safety and effects of potential vaccines, biologics, and treatments against influenza. The trial focuses on healthy adults aged 18 to 45 years and aims to safely and consistently cause symptomatic influenza virus infection using a specific H3N2 strain. Participants will receive a single intranasal dose of the RG-ATexas712017 H3N2 influenza virus or a placebo. The study includes three different dose groups administered sequentially. This Phase 1 trial is designed to assess how the virus infection develops and to evaluate safety across different viral doses. During the study, participants will be closely monitored from Day 1 up to Day 85. Researchers will track symptomatic influenza infection, viral shedding, peak viral load, immune responses, and safety profiles through clinical assessments, laboratory tests, and questionnaires. Participants will complete eDiary cards and attend follow-up visits to provide detailed data on infection progression and immune reactions.
CONDITIONS
Brief Title
Establishing a Controlled Human Infection Model for Influenza H3N2 as a Foundation for Pandemic Preparedness
Research Team
N
Nick Bartlett
H
Hannah Munday
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here